Modern Applications of Bioequivalence & Bioavailability (MABB)

Modern Applications of Bioequivalence & Bioavailability is committed to publish original research in all aspects of areas of Bioequivalence and Bioavailability through rapid peer-review process. MABB aims to promote more information about Bioequivalence and Bioavailability and its related science to enhance the exchange of scientific knowledge among peers. Juniper strongly welcomes researchers for submission of papers in different formats like original research papers, review articles, News, short communications, Opinions, letter to editors on a breadth of topics related to Regulatory Requirements in Bioequivalence, Biosimilars, Advances in Bioavailability, FDA Bioequivalence, Absolute bioavailability, Biowaivers, Clinical pharmacy, Toxicology, Biosimilars, Bioaccessibility, and other interesting topics related to Bioequivalence and Bioavailability. The journal covers a wide range of topics including comparative bioavailability studies, generic drug development, drug absorption mechanisms, pharmacodynamic evaluations, therapeutic equivalence, and regulatory guidelines for drug approval. It also includes research on novel drug delivery systems, nanomedicine applications, controlled release formulations, and clinical trial methodologies related to pharmacokinetic profiling. MABBA aims to bridge the gap between laboratory research and clinical application by promoting studies that ensure the safety, efficacy, and quality of pharmaceutical products. It supports global research contributions from academia, industry, and regulatory agencies, encouraging innovation in drug evaluation methodologies. Since its inception in 2017, the journal has contributed to the dissemination of knowledge in bioequivalence and bioavailability sciences. Being an open-access journal, it allows unrestricted access to published content, promoting worldwide scientific communication and advancement in pharmaceutical research and regulatory compliance.

Modern Applications of Bioequivalence & Bioavailability (MABB) is :-

• International, Peer-Reviewed, Open Access, Refereed, comparative bioavailability studies, generic drug development, drug absorption mechanisms, pharmacodynamic evaluations, therapeutic equivalence, regulatory guidelines for drug approval, research on novel drug delivery systems, nanomedicine applications, controlled release formulations, Absolute bioavailability, Biowaivers, Clinical pharmacy, Toxicology, Biosimilars, Bioaccessibility , Online , Continuously Journal

• UGC Approved, ISSN Approved: P-ISSN E-ISSN: 2577-2856, Established: 2017,
• Does Not Provide Crossref DOI

• Not indexed in Scopus, WoS, DOAJ, PubMed, UGC CARE